Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NNOX.

← Back to Free Index

NNOX

Analysis as of: 2026-05-28

NANO-X IMAGING LTD

Nanox develops digital tomosynthesis imaging systems and sells related imaging AI, cloud, teleradiology, and healthcare IT solutions to providers and imaging partners.

ai cloud healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Managed Imaging Optionality, Real Execution Risk

The equity offers real upside if low-cost 3D systems become recurring software-and-services nodes rather than isolated device sales. The debate is no longer product clearance; it is financing, activation speed, and whether attached workflow revenue becomes sticky enough to justify a rerating.

Analysis

Thesis

Nanox is a distressed real option on turning FDA-cleared low-cost 3D imaging hardware into a managed imaging utility with cloud, AI, remote reads, and healthcare IT attached; if financing and activations clear, each live site can become a recurring revenue node and the equity can rerate far faster than today’s scale implies.

Last Economy Alignment

Cheaper AI helps imaging interpretation, workflow automation, and remote reading, but Nanox captures only part of that value because hardware, regulation, and incumbent bundles still control much of the stack.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

8.2x (from 5 most recent analyses)

Reasoning

The upside case is not about selling more boxes alone. It is about proving that live sites become recurring scan, software, and service nodes with better attach and utilization over time. If that happens, investors can value the business as a small installed-base imaging stack rather than a speculative device launch. I still keep the rerating well below premium software peers because financing needs, regulatory gates, and incumbent OEM competition remain real.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is a sequence-risk story: liquidity first, then activations, then proof that each live site carries attractive recurring mix. The upside is large because today’s revenue base is tiny and the product is cleared, but failure on financing, regulatory timing, distributor execution, or unit economics can cap growth and force dilution before the flywheel forms.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Since May 19, 2026, no new official operating update or financing disclosure has changed the core setup; the debate is still anchored to the April 20, 2026 results and the May 4, 2026 channel update.
Recent U.S. channel announcements still improve the top-of-funnel story, but there is still no fresh disclosure proving a step-up in live revenue-producing site count.
The liquidity overhang remains unresolved in public filings, so the market is still likely to treat new commercial headlines as secondary to financing and activation evidence.

Thesis update

No major change. The added U.S. channel breadth improves optionality, but the core thesis still depends on converting placements into live recurring sites and extending runway.

Forecast update

I am a bit more disciplined on the rerating ceiling because the model is still hardware-heavy and likely needs more capital before the recurring mix is proven.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.27

It controls an FDA-cleared imaging box plus the cloud, reads, and IT plumbing around it, so each live site can become a small tollbooth for scans and workflow. But it does not own the deepest choke point in medical imaging, and bigger vendors with financing, service teams, and broader product suites can still squeeze it.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$6.00

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research